Guggenheim analyst Yatin Suneja initiated GW Pharmaceuticals with a Buy rating and $178 price target, stating that the company’s “state-of-the-art Cannabis-based platform” has the potential to deliver drugs for several neurological disorders and lead drug, Epidiolex, should have a successful launch.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.